ConductScience.org, home

Paper36935431

Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience.

Gurav M and 7 others. J Cancer Res Clin Oncol, 2023. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience. Papers, record 36935431. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36935431

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience.
PubMed
Journal
J Cancer Res Clin Oncol
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
4
iCite
Relative citation ratio, by iCite
0.35
iCite
Revised in PubMed
2025-07-19
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gurav MMamtahttps://orcid.org/0000-0002-8618-6314
2Epari SSridharhttps://orcid.org/0000-0002-1038-5755
3Gogte PPrachi
4Pai TTruptihttps://orcid.org/0000-0001-5160-3897
5Deshpande GGaurihttps://orcid.org/0000-0002-9895-2995
6Karnik NNupurhttps://orcid.org/0000-0002-4707-0730
7Shetty OOmshreehttps://orcid.org/0000-0003-1996-4347
8Desai SSangeeta

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Proto-Oncogene Proteins B-rafMajor topic
Lung NeoplasmsMajor topic
Humans
Proto-Oncogene Proteins p21(ras)
Mutation
ErbB Receptors
Receptor Protein-Tyrosine Kinases
High-Throughput Nucleotide Sequencing

Source PubMed

Download CSV of topics

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127678269Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.Virchows Arch2017https://conductscience.org/library/papers/27678269PubMed
229250205Next generation sequencing: clinical applications in solid tumours.Memo2017https://conductscience.org/library/papers/29250205PubMed
331445211A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.J Mol Diagn2019https://conductscience.org/library/papers/31445211PubMed
429786478Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke.Int J Stroke2018https://conductscience.org/library/papers/29786478PubMed
531251989Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis.J Mol Diagn2019https://conductscience.org/library/papers/31251989PubMed
626868357Precision oncology: origins, optimism, and potential.Lancet Oncol2016https://conductscience.org/library/papers/26868357PubMed
730766968Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.JCO Precis Oncol2018https://conductscience.org/library/papers/30766968PubMed
826680590Advances in clinical next-generation sequencing: target enrichment and sequencing technologies.Expert Rev Mol Diagn2016https://conductscience.org/library/papers/26680590PubMed
933127962Signal transduction pathway mutations in gastrointestinal (GI) cancers: a systematic review and meta-analysis.Sci Rep2020https://conductscience.org/library/papers/33127962PubMed
1026423591Overview of Target Enrichment Strategies.Curr Protoc Mol Biol2015https://conductscience.org/library/papers/26423591PubMed
1135135162Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research Experience.JCO Precis Oncol2018https://conductscience.org/library/papers/35135162PubMed
1232947236KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report.Transl Oncol2020https://conductscience.org/library/papers/32947236PubMed
1330089598The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.Lung Cancer2018https://conductscience.org/library/papers/30089598PubMed
1421829508PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.PLoS One2011https://conductscience.org/library/papers/21829508PubMed
1529625050Oncogenic Signaling Pathways in The Cancer Genome Atlas.Cell2018https://conductscience.org/library/papers/29625050PubMed
1633009475Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers.Sci Rep2020https://conductscience.org/library/papers/33009475PubMed
1722797725Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population.Nat Genet2012https://conductscience.org/library/papers/22797725PubMed
1826212640Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity.Sci Rep2015https://conductscience.org/library/papers/26212640PubMed
1927242894TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients.Front Genet2016https://conductscience.org/library/papers/27242894PubMed
2029954777Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative.Clin Cancer Res2018https://conductscience.org/library/papers/29954777PubMed

See all 38 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42010540Genomic landscape of cholangiocarcinoma in India: ethnic variants and implications for targeted therapy.BMC Cancer2026https://conductscience.org/library/papers/42010540PubMed
41108159Dual inhibition of BRAF for cancer treatment: advances and therapeutic potential.Future Med Chem2025https://conductscience.org/library/papers/41108159PubMed
38717047Microfluidics-based EGFR mutation detection and its implication in the resource-limited clinical setting.Int J Exp Pathol2024https://conductscience.org/library/papers/38717047PubMed

Download CSV of cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALK238PubTator's text mininghttps://conductscience.org/library/genes/238NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
NRAS4893PubTator's text mininghttps://conductscience.org/library/genes/4893NCBI Gene
PIK3CA5290PubTator's text mininghttps://conductscience.org/library/genes/5290NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36935431

GET https://conductscience.org/api/papers/v1/36935431/references?page=2